ANGO · Angiodynamics Inc - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · ANGO

1Y 3Y 5Y Max

Annual Quarterly

Income Statement

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$292.50M	$303.91M	$338.75M	$264.16M	$291.01M	$264.16M
Cost of Revenue	$134.79M	$149.22M	$164.51M	$150.49M	$134.22M	$113.89M
Gross Profit	$157.71M	$154.70M	$174.25M	$165.73M	$156.79M	$150.27M
R&D	$26.22M	$31.51M	$29.88M	$30.74M	$36.39M	$29.68M
SG&A	$42.09M	$41.16M	$40.00M	$38.45M	$35.92M	$37.87M
Total Operating Expenses	$197.66M	$401.63M	$225.43M	$194.20M	$192.07M	$317.37M
D&A	$25.80M	$27.71M	$30.87M	$29.35M	$25.92M	$23.80M
Operating Income	($39.95M)	($192.44M)	($51.18M)	($28.47M)	($35.28M)	($167.10M)
Interest Expense	-	($1.61M)	$2.70M	$688.0K	$861.0K	$907.0K
Income Tax	($39.0K)	($7.29M)	($2.00M)	($3.40M)	($4.50M)	($1.35M)
Net Income	($33.99M)	($184.35M)	($52.44M)	($26.55M)	($31.55M)	($166.79M)
EPS - Basic	($0.83)	($4.59)	($1.33)	($0.68)	($0.82)	($4.39)
EPS - Diluted	($0.83)	($4.59)	($1.33)	($0.68)	($0.82)	($4.39)

Balance Sheet

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Cash & Equivalents	$55.89M	$76.06M	$44.62M	$28.82M	$48.16M	$54.44M
Accounts Receivable	$42.89M	$43.61M	$52.83M	$52.30M	$35.41M	$31.26M
Inventory	$62.01M	$60.62M	$55.33M	$51.39M	$48.61M	$59.91M
Accounts Payable	$33.29M	$37.75M	$40.45M	$28.05M	$19.63M	$19.10M
Current Assets	$168.32M	$193.25M	$163.54M	$143.34M	$140.88M	$152.91M
Total Assets	$280.14M	$317.67M	$532.64M	$552.75M	$561.44M	$594.21M
Current Liabilities	$76.20M	$91.16M	$83.83M	$74.32M	$57.58M	$51.45M
Long-term Debt	-	$0	$25.00M	-	-	-
Total Liabilities	$97.17M	$112.08M	$154.34M	$128.26M	$121.98M	$139.34M
Stockholders' Equity	$182.97M	$205.59M	$378.30M	$424.49M	$439.46M	$454.87M
Retained Earnings	($429.20M)	($395.20M)	($210.85M)	($158.41M)	($131.87M)	($100.32M)

Cash Flow

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Operating Cash Flow	($10.13M)	($28.16M)	$78.0K	($7.19M)	$24.09M	($14.55M)
Investing Cash Flow	($10.18M)	$123.72M	($9.75M)	($19.31M)	($13.71M)	($63.34M)
Financing Cash Flow	($255.0K)	($64.25M)	$25.42M	$7.68M	($16.99M)	($95.24M)
CapEx	$4.46M	$2.52M	$3.81M	$4.30M	$5.19M	$7.24M
Free Cash Flow	($14.59M)	($30.68M)	($3.73M)	($11.49M)	$18.91M	($21.79M)

Ratios

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Profitability
Gross margin	53.9%	50.9%	51.4%	62.7%	53.9%	56.9%
Operating margin	-13.7%	-63.3%	-15.1%	-10.8%	-12.1%	-63.3%
EBITDA margin	-4.8%	-54.2%	-6.0%	0.3%	-3.2%	-54.2%
Net margin	-11.6%	-60.7%	-15.5%	-10.0%	-10.8%	-63.1%
Free cash flow margin	-5.0%	-10.1%	-1.1%	-4.4%	6.5%	-8.2%
FCF / Net income	0.43	0.17	0.07	0.43	-0.60	0.13
R&D / Revenue	9.0%	10.4%	8.8%	11.6%	12.5%	11.2%
SG&A / Revenue	14.4%	13.5%	11.8%	14.6%	12.3%	14.3%
Effective tax rate	-	-	-	-	-	-
Return on assets	-12.1%	-58.0%	-9.8%	-4.8%	-5.6%	-28.1%
Return on equity	-18.6%	-89.7%	-13.9%	-6.3%	-7.2%	-36.7%
Return on invested capital	-	-73.9%	-10.0%	-	-	-
Liquidity
Current ratio	2.21	2.12	1.95	1.93	2.45	2.97
Quick ratio	1.40	1.46	1.29	1.24	1.60	1.81
Cash ratio	0.73	0.83	0.53	0.39	0.84	1.06
Leverage
Debt / Equity	-	0.00	0.07	-	-	-
Debt / Assets	-	0.00	0.05	-	-	-
Debt / EBITDA	-	-	-	-	-	-
Interest coverage	-	119.2x	-18.9x	-41.4x	-41.0x	-184.2x
Equity multiplier	1.53	1.55	1.41	1.30	1.28	1.31
Liabilities / Assets	0.35	0.35	0.29	0.23	0.22	0.23
Efficiency
Asset turnover	1.04	0.96	0.64	0.48	0.52	0.44
Inventory turnover	2.17	2.46	2.97	2.93	2.76	1.90
Days sales outstanding	54d	52d	57d	72d	44d	43d
Days inventory outstanding	168d	148d	123d	125d	132d	192d
Days payable outstanding	90d	92d	90d	68d	53d	61d
Cash conversion cycle	131d	108d	90d	129d	123d	174d
Valuation
P / E	-	-	-	-	-	-
P / B	2.3x	1.2x	1.0x	1.8x	2.0x	0.9x
P / S	1.4x	0.8x	1.1x	2.9x	3.0x	1.5x
EV / EBITDA	-	-	-	839.3x	-	-
Growth
Revenue growth (YoY)	-3.8%	-10.3%	28.2%	-9.2%	10.2%	-2.4%
Revenue CAGR (3y)	3.5%	1.5%	8.6%	-0.8%	-6.3%	-8.9%
Revenue CAGR (5y)	2.1%	2.3%	-0.9%	-5.5%	-3.8%	-5.8%
Gross profit growth (YoY)	1.9%	-11.2%	5.1%	5.7%	4.3%	-3.7%
Operating income growth (YoY)	79.2%	-276.0%	-79.8%	19.3%	78.9%	-1678.4%
Net income growth (YoY)	81.6%	-251.5%	-97.5%	15.9%	81.1%	-
EPS growth (YoY)	81.9%	-245.1%	-95.6%	17.1%	81.3%	-
EPS CAGR (3y)	-	-	-	-	-	-
EPS CAGR (5y)	-	-	-	-	-	-
FCF growth (YoY)	52.4%	-721.5%	67.5%	-	-	-
FCF CAGR (5y)	-	-	-	-	-15.1%	-
Book value growth (YoY)	-11.0%	-45.7%	-10.9%	-3.4%	-3.4%	-26.0%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-05-31.

Business segments

$292.50M total

Med Device Segment$165.84M · 56.7%

Med Tech Segment$126.65M · 43.3%

Product / service

$250.98M total

Med Device Segment$141.73M · 56.5%

Med Tech Segment$109.25M · 43.5%

Geographic

$334.01M total

US$250.98M · 75.1%

International$41.52M · 12.4%

Non Us$41.52M · 12.4%

Stability scores

Altman Z′

FY 2025 · bankruptcy risk

0.33

Distress

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2025 · 9-point quality

5/9

Neutral

✗Net income positive
✗Operating cash flow positive
✓ROA improved YoY
✓Cash flow > net income
-Long-term debt decreased
✓Current ratio improved
✗No share dilution
✓Gross margin improved
✓Asset turnover improved

Peer comparison

Same SIC group: Surgical & Medical Instruments & Apparatus

Company	Revenue (last FY)	Net margin	ROE
BSX	$20.07B	14.4%	12.0%
LMAT	$249.60M	23.1%	14.7%
TNDM	$1.01B	-20.2%	-131.9%
SYK	$25.12B	12.9%	14.5%
MMM	$24.95B	13.0%	69.1%

Comparing ANGIODYNAMICS INC against the 5 most active filers in the same SIC group.